Treatment of inflammatory bowel disease (IBD)

被引:298
作者
Pithadia, Anand B. [1 ]
Jain, Sunita [1 ]
机构
[1] LM Coll Pharm, Dept Pharmacol, Ahmadabad 380009, Gujarat, India
关键词
inflammatory bowel disease (IBD); 5-aminosalicylates; corticosteroids; infliximab; PLACEBO-CONTROLLED TRIAL; ACTIVE ULCERATIVE-COLITIS; RANDOMIZED CONTROLLED-TRIAL; FACTOR-KAPPA-B; ALOE-VERA GEL; CROHNS-DISEASE; DOUBLE-BLIND; ORAL BUDESONIDE; MEDICAL THERAPY; PILOT TRIAL;
D O I
10.1016/S1734-1140(11)70575-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, which includes Crohn's disease (CD) and ulcerative colitis (UC). These diseases have become important health problems. Medical therapy for IBD has advanced dramatically in the last decade with the introduction of targeted biologic therapies, the optimization of older therapies, including drugs such as immunomodulators and 5-aminosalicylic acid (5-ASA), and a better understanding of the mucosal immune system and the genetics involved in the pathogenesis of IBD. The goal of IBD therapy is to induce and maintain remission. The current treatment paradigm involves a step-up approach, moving to aggressive, powerful therapies only when milder therapies with fewer potential side effects fail or when patients declare themselves to have an aggressive disease. This review focuses on the current treatments for inflammatory bowel disease.
引用
收藏
页码:629 / 642
页数:14
相关论文
共 64 条
[1]   Corticosteroids and immunomodulators: Postoperative infectious complication risk in inflammatory bowel disease patients [J].
Aberra, FN ;
Lewis, JD ;
Hass, D ;
Rombeau, JL ;
Osborne, B ;
Lichtenstein, GR .
GASTROENTEROLOGY, 2003, 125 (02) :320-327
[2]   Preliminary study of ciprofloxacin in active Crohn's disease [J].
Arnold, GL ;
Beaves, MR ;
Pryjdun, VO ;
Mook, WJ .
INFLAMMATORY BOWEL DISEASES, 2002, 8 (01) :10-15
[3]   Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases [J].
Barnes, PJ ;
Larin, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) :1066-1071
[4]  
BELLO C, 1991, AM J GASTROENTEROL, V86, P460
[5]   VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis [J].
Bibiloni, R ;
Fedorak, RN ;
Tannock, GW ;
Madsen, KL ;
Gionchetti, P ;
Campieri, M ;
De Simone, C ;
Sartor, RB .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (07) :1539-1546
[6]   Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables [J].
Camma, C ;
Giunta, M ;
Rosselli, M ;
Cottone, M .
GASTROENTEROLOGY, 1997, 113 (05) :1465-1473
[7]  
Carrier J, 2003, CANCER EPIDEM BIOMAR, V12, P1262
[8]   LONG-TERM NEOPLASIA RISK AFTER AZATHIOPRINE TREATMENT IN INFLAMMATORY BOWEL-DISEASE [J].
CONNELL, WR ;
KAMM, MA ;
DICKSON, M ;
BALKWILL, AM ;
RITCHIE, JK ;
LENNARDJONES, JE .
LANCET, 1994, 343 (8908) :1249-1252
[9]   Protective effects of M40403, a superoxide dismutase mimetic, in a rodent model of colitis [J].
Cuzzocrea, S ;
Mazzon, E ;
Dugo, L ;
Caputi, AP ;
Riley, DP ;
Salvemini, D .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 432 (01) :79-89
[10]  
Dotan I, 2005, CURR OPIN GASTROEN, V21, P426